Gilvetmab
Product Specifications
CAS Number
1808081-43-7
Target
PD-1/PD-L1
Related Pathways
Cell Cycle/Checkpoint, Immunology/Inflammation, Apoptosis
Purity
0.979
Bioactivity
Gilvetmab is a caninized anti-PD-1 monoclonal antibody that has obtained conditional approval for veterinary use in dogs. Gilvetmab is under active research for stage I, II, or III mast cell tumors and stage II or III melanoma. it is an competitive immune checkpoint inhibitor, attracting interests in the cancer research field.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog